New York - Topical 5-fluorouracil 5 percent cream (Efudex, Valeant) appears to be a low-risk, low-cost, rapidly effective and well-tolerated treatment for common warts in children, according to the results of a pilot study presented by Bari B. Cunningham, M.D., at the American Academy of Dermatology's Academy `04, here this summer.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.